Intrathoracic progression was significantly reduced with radiotherapy.
Extensive-stage small-cell lung cancer (ES-SCLC) is primarily treated with systemic chemotherapy, and in patients with a near-complete response, prophylactic cranial irradiation (PCI) is routinely offered. Patients are monitored until disease progression. However, persistent intrathoracic disease often remains.
To assess the use of consolidative thoracic radiotherapy for intrathoracic disease, investigators conducted a phase III, multicenter, randomized, controlled trial involving 498 ES-SCLC patients. Those who responded to systemic chemotherapy were randomized to receive PCI with thoracic radiation (30 Gy in 10 fractions) or PCI alone (controls).
No significant difference in 1-year overall survival (OS; the primary endpoint) was observed be…
Reviewing Author
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb